pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN® for use within the National Health Service (NHS) Scotland under a simple patient access scheme. ILUVIEN will be available in the NHS Scotland to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies in pseudophakic eyes (those that have undergone cataract surgery).
The NHS National Services Scotland has agreed to the patient access scheme in relation to the supply of ILUVIEN for this indication on behalf of all purchasing sites in the NHS in Scotland. Retreatment with ILUVIEN, which provides a therapeutic benefit for up to 36 months, will be covered when the patient has previously responded to ILUVIEN and vision has deteriorated to less than 20/32.
"The acceptance of ILUVIEN for DME by the NHS Scotland is excellent news. This follows the November 2013 recommendation of ILUVIEN by the U.K. National Institute for Health and Care Excellence (NICE) as an option for this indication and rapid implementation of the recommendation by the NHS in England," said Paul Ashton, president and chief executive officer of pSivida.
SOURCE pSivida Corp.